Significance of N-acetylcysteine in clinical practice
https://doi.org/10.18093/0869-0189-2023-33-5-679-688
Abstract
N-acetylcysteine (NAC) is a mucolytic and antioxidant with a variety of properties. The clinical use of NAC spans more than 35 years, during which the emphasis has been on a multifaceted action and broad spectrum of therapeutic indications. Information is available on the efficacy of NAC in the prevention of contrast-induced nephropathy, studies on the role of NAC in the treatment of pulmonary and coronary disease, etc. The purpose of this review is to analyze the efficacy and safety of NAC in respiratory clinical practice. Conclusion. NAC is a drug with a unique variety of properties and treatment options. The drug has proven its efficacy and safety in real pulmonology practice.
Supporting agencies: The article was published with support from the Zambon Group. The Zambon Group provided funding for the scientific research, but not the drug products. The representatives of the sponsor did not participate in the writing of this article and are not responsible for the content of the article or any financial or other agreements with third parties in connection with this article. The opinions of the sponsor’s representatives may differ from those of the authors of the article and the editorial board.
About the Authors
I. V. Leshchenko
Federal State Budgetary Educational Institution of Higher Education “Ural Federal State Medical University”, Healthcare Ministry of Russia; Ural Federal Research Institute of Phthisiology and Pulmonology – a Branch of National Medical Research Center for Phthisiology, Pulmonology and Infectious Diseases, Healthcare Ministry of Russia; Limited Liability Company “Novaya bol’nitsa” Clinical Association
Russian Federation
Competing Interests:
Russian Federation
Igor V. Leshсhenko, Doctor of Medicine, Professor, Department of Phthisiology and Pulmonology, Federal State Budgetary Educational Institution of Higher Education “Ural Federal State Medical University”, Healthcare Ministry of Russia; Chief Researcher, Ural Federal Research Institute of Phthisiology and Pulmonology – a Branch of National Medical Research Center for Phthisiology, Pulmonology and Infectious Diseases, Healthcare Ministry of Russia; Scientific Director, Limited Liability Company “Novaya bol’nitsa” Clinical Association, Chief Freelance Pulmonologist, Healthcare Ministry of the Sverdlovsk Region, Honored Doctor of the Russian Federation
ul. Repina 3, Ekaterinburg, 620028; ul. 22-go Parts’ezda 50, Ekaterinburg, 620039; ul. Zavodskaya 29, Ekaterinburg, 620109
tel.: (343) 246-44-75
Competing Interests:
The authors declare no conflict of interest.
N. A. Esaulova
Federal State Budgetary Educational Institution of Higher Education “Ural Federal State Medical University”, Healthcare Ministry of Russia; Ural Federal Research Institute of Phthisiology and Pulmonology – a Branch of National Medical Research Center for Phthisiology, Pulmonology and Infectious Diseases, Healthcare Ministry of Russia
Russian Federation
Competing Interests:
Russian Federation
Natalya A. Esaulovа, Candidate or Medicine, Associate Professor, Department of Phthisiology and Pulmonology, Federal State Budgetary Educational Institution of Higher Education “Ural Federal State Medical University”, Healthcare Ministry of Russia; Pulmonologist, Ural Federal Research Institute of Phthisiology and Pulmonology – a Branch of National Medical Research Center for Phthisiology, Pulmonology and Infectious Diseases, Healthcare Ministry of Russia
ul. Repina 3, Ekaterinburg, 620028; ul. 22-go Parts’ezda 50, Ekaterinburg, 620039
tel.: (343) 246-44-75
Competing Interests:
The authors declare no conflict of interest.
References
1. Webb W.R. Clinical evaluation of a new mucolytic agent acetylcysteine. J. Thorac. Cardiovasc. Surg. 1962; 44 (3): 330–343. DOI: 10.1016/S0022-5223(19)32956-3.
2. Reas H.W. The effect of N-acetylcysteine on the viscosity of tracheobronchial secretion in cystic fibrosis of the pancreas. J. Pediatr. 1963; 62: 31–35. DOI: 10.1016/s0022-3476(63)80067-0.
3. De Vries N., De Flora S. N-acetyl-l-cysteine. J. Cell Biochem. 1993; 17F: 270–278. DOI: 10.1002/jcb.240531040.
4. De Flora S., Izzotti A., D'Agostini F., Cesarone C.F. Antioxidant activity and other mechanisms of thiols involved in chemoprevention of mutation and cancer. Am. J. Med. 1991; 91 (3, Suppl. 3): 122–130S. DOI: 10.1016/0002-9343(91)90295-9.
5. De Flora S., Cesarone C.F., Balansy R.M. et al. Chemopreventive properties and mechanisms of N-acetylcysteine. The experimental background. J. Cell Biochem. Suppl. 1995; 22: 33–41. DOI: 10.1002/jcb.240590806.
6. Fishbane S., Durham J.H., Marzo K., Rudnick M. N-acetylcysteine in the prevention of radiocontrastinduced nephropathy. J. Am. Soc. Nephrol. 2004; 15 (2): 251–260. DOI: 10.1097/01.asn.0000107562.68920.92.
7. Ignarro L. Endothelium derived nitric oxide: pharmacology and relationship to the actions of organic esters. Pharm. Res. 1989; 6 (8): 651–659. DOI: 10.1023/a:1015926119947.
8. Moklesi B., Leikin J.B., Murray P., Corbridge T.C. Adult toxicology in critical care. Part II: specific poisoning. Chest. 2003; 123 (3): 897–922. DOI: 10.1378/chest.123.3.897.
9. Smilkstein M.J., Knapp G.L., Kulig K.W., Rumack B.H. Efficacy of oral N-acetylcysteine in the treatment of accetaminophen overdose. Analysis of the national multicenter study (1976 to 1985). N. Engl. J. Мed. 1988; 319 (24): 1557–1562. DOI: 10.1056/NEJM198812153192401.
10. Tenório M.C.D.S., Graciliano N.G., Moura F.A. et al. N-acetylcysteine (NAC): impacts on human health. Antioxidants. 2021; 10 (6): 967. DOI: 10.3390/antiox10060967.
11. Roveta A.M., Debbia E., Schito G., Marchese A. Comparison of the activity of N-acetylcisteine, ambroxol, bromexine and sobrerol on Staphylococcus aureus biofilms. GIMMOC. 2004; 8: 1–12.
12. Blasi F., Clive Page C., Rossolini G.M. et al. The effect of N-acetylcysteine on biofilms: Implications for the treatment of respiratory tract infections. Respir. Med. 2016; 117: 190–197. DOI: 10.1016/j.rmed.2016.06.015.
13. Van Schooten F.J., Besaratinia A., De Flora S. et al. Effects of oral administration of N-acetyl-L-cysteine: a multi-biomarker study in smokers. Cancer Epidemiol. Biomarkers Prev. 2002; 11 (2): 167–175. Available at: https://aacrjournals.org/cebp/article/11/2/167/166561/Effects-of-Oral-Administration-of-N-Acetyl-l
14. Papadopoulou E., Hansel J., Lazar Z. et al. Mucolytics for acute exacerbations of chronic obstructive pulmonary disease: a meta-analysis. Eur. Respir. Rev. 2023; 32 (167): 220141. DOI: 10.1183/16000617.0141-202.
15. Wei J., Pang C.S., Han J., Yan H. Effect of orally administered N-acetylcysteine on chronic bronchitis: a meta-analysis. Adv. Ther. 2019; 36 (12): 3356–3367. DOI: 10.1007/s12325-019-01111-4.
16. Bisetti A., Mancini C. Mucolytic activity of erdosteine: Double blind clinical trial vs. placebo. Arch. Med. Int. 1995; 47 (4): 89–97. Available at: https://www.researchgate.net/publication/279701340_Mucolytic_activity_of_erdosteine_double_blind_clinical_trial_vs_placebo
17. Li W., Mao B., Wang G. et al. Effect of tanreqing injection on treatment of acute exacerbation of chronic obstructive pulmonary disease with Chinese medicine syndrome of retention of phlegm and heat in Fei. Chin. J. Integr. Med. 2010; 16 (2): 131–137. DOI: 10.1007/s11655-010-0131-y.
18. Marchioni C.F., Polu J.M., Taytard A. et al. Evaluation of efficacy and safety of erdosteine in patients affected by chronic bronchitis during an infective exacerbation phase and receiving amoxycillin as basic treatment (ECOBES, European Chronic Obstructive Bronchitis Erdosteine Study). Int. J. Clin. Pharmacol. Ther. 1995; 33 (11): 612–618. Available at: https://eurekamag.com/research/008/633/008633824.php
19. Zhang Q., Ju Y., Ma Y,. Wang T. N-acetylcysteine improves oxidative stress and inflammatory response in patients with community acquired pneumonia: a randomized controlled trial. Medicine (Baltimore). 2018; 97 (45): e13087. DOI: 10.1097/MD.0000000000013087.
20. Buha I., Mirić M., Agić A. et al. A randomized, double-blind, placebo-controlled study evaluating the efficacy of propolis and N-acetylcysteine in exacerbations of chronic obstructive pulmonary disease. Eur. Rev. Med. Pharmacol. Sci. 2022; 26 (13): 4809–4815. DOI: 10.26355/eurrev_202207_29206.
21. Papi A., Zheng J., Criner G.J. et al. Impact of smoking status and concomitant medications on the effect of high-dose N-acetylcysteine on chronic obstructive pulmonary disease exacerbations: a post-hoc analysis of the PANTHEON study. Respir. Med. 2019; 147: 37–43. DOI: 10.1016/j.rmed.2018.12.014.
22. Riise G.C., Larsson S., Larsson P. et al. The intrabronchial microbial flora in chronic bronchitis patients: a target for N-acetylcysteine therapy. Eur. Respir. J. 1994; 7 (1): 94–101. DOI: 10.1183/09031936.94.07010094.
23. Holdiness M.R. Clinical pharmacokinetics of N-acetylcysteine. Clin. Pharmacokinet. 1991; 20 (2): 123–134. DOI: 10.2165/00003088-199120020-00004.
24. Decramer M., Rutten-van Mölken M., Dekhuijzen P.N. et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomized placebo-controlled trial. Lancet. 2005; 365 (9470): 1552–1560. DOI: 10.1016/S0140-6736(05)66456-2.
25. Ministry of Health of the Russian Federation. [Chronic obstructive pulmonary disease: Clinical guidelines]. 2021. Available at: https://spulmo.ru/upload/kr/HOBL_2021.pdf?ysclid=lmajgdp9yl326639003 (in Russian).
26. Zheng J.P., Wen F.Q., Bai C.X. et al. Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial. Lancet Respir. Med. 2014; 2 (3): 187–194. DOI: 10.1016/S2213-2600(13)70286-8.
27. Ministry of Health of the Russian Federation. [The Temporary Guidelines: Prevention, diagnosis and treatment of new coronavirus infection (COVID-19)]. Version 17 (December 14, 2022). Available at: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/061/254/original/%D0%92%D0%9C%D0%A0_COVID-19_V17.pdf?1671088207 (in Russian).
28. Chousterman B.G., Swirski F.K., Weber G.F. Cytokine storm and sepsis disease pathogenesis. Semin. Immunopathol. 2017; 39 (5): 517–528. DOI: 10.1007/s00281-017-0639-8.
29. Ibrahim H., Perl A., Smith D. et al. Therapeutic blockade of inflammation in severe COVID-19 infection with intravenous N-acetylcysteine. Clin. Immunol. 2020; 219: 108544. DOI: 10.1016/j.clim.2020.108544.
30. Gainitdinova V.V., Avdeev S.N., Merzhoeva Z.M. et al. [N-acetylcysteine as a part of complex treatment of moderate COVID-associated pneumonia]. Pul'monologiya. 2021; 31 (1): 21–29. DOI: 10.18093/0869-0189-2021-31-1-21-29 (in Russian).
31. Zafarullah M., Li W.Q., Sylvester J., Ahmad M. Molecular mechanisms of N-acetylcysteine actions. Cell. Mol. Life Sci. 2003; 60 (1): 6–20. DOI: 10.1007/s000180300001.
32. Sadowska A.M., Manuel-Y-Keenoy B., De Backer W.A. Antioxidant and anti-inflammatory efficacy of NAC in the treatment of COPD: discordant in vitro and in vivo dose-effects: a review. Pulm. Pharmacol. Ther. 2007; 20 (1): 9–22. DOI: 10.1016/j.pupt.2005.12.007.
33. Wolcott, R.D., Ehrlich, G.D. Biofilms and chronic infections. JAMA. 2008; 299 (22): 2682–2684. DOI: 10.1001/jama.299.22.2682.
34. Pérez-Giraldo C., Rodríguez-Benito A., Morán F.J. et al. Influence of N-acetylcysteine on the formation of biofilm by Staphylococcus epidermidis. J. Antimicrob Chemother. 1997; 39 (5): 643–646. DOI: 10.1093/jac/39.5.643.
35. Ministry of Health of the Russian Federation. [Acute bronchitis in adults: Clinical guidelines]. 2022. Available at: https://spulmo.ru/upload/kr/OB_2022.pdf?ysclid=lmak85iv12292497995 (in Russian).
36. Izquierdo J.L., Soriano J.B., González Y. et al. Use of N-acetylcysteine at high doses as an oral treatment for patients hospitalized with COVID-19. Sci. Prog. 2022; 105 (1): 368504221074574. DOI: 10.1177/00368504221074574.
Supplementary files
Review
For citations:
Leshchenko I.V., Esaulova N.A. Significance of N-acetylcysteine in clinical practice. PULMONOLOGIYA. 2023;33(5):679-688. (In Russ.) https://doi.org/10.18093/0869-0189-2023-33-5-679-688
Views:
3002
Email this article 